Loading...
•
Sep 30, 2024
BioNano Q3 2024 Earnings Report
Bionano's Q3 2024 performance reflected improving momentum for OGM utilization and sales of flowcells, but overall revenues were below expectations due to delayed system orders and a write-down of aged receivables.
Key Takeaways
Bionano reported a 35% decrease in revenue compared to Q3 2023, with total revenue of $6.1 million. The company highlighted improving momentum for OGM utilization and flowcell sales, but revenues were impacted by delayed system orders and a write-down of aged receivables. Cash burn was significantly lower than the prior year period due to the reorganization plan to decrease expenses.
Q3 2024 revenue was $6.1 million, a 35% decrease compared to Q3 2023.
Installed base of OGM systems increased by 22% year-over-year, reaching 368 systems.
Flowcell sales increased by 27% year-over-year, with 7,835 nanochannel array flowcells sold.
GAAP operating expense decreased by 69% year-over-year.
BioNano
BioNano
BioNano Revenue by Segment
Revenue by Segment
Product Revenue
CapyFin.comService and Other Revenue
CapyFin.com Forward Guidance
Bionano anticipates continued growth in OGM adoption and flowcell sales, driven by positive clinical data and CPT code implementation. The company expects to maintain its focus on expense management and strategic productivity initiatives to extend its cash runway.
Positive Outlook
- Ongoing CPT code implementation and pricing announcement for OGM in cytogenomic genome-wide analysis.
- Potential additional gross proceeds of up to $20.0 million from the exercise of Series A and Series B warrants.
- Publication of first multi-site study to analyze the utility of OGM in Multiple Myeloma.
- Recent Peer-reviewed highlighted applications of OGM in blood cancers.
- Closing of an additional $3.0 million registered direct offering
Challenges Ahead
- Overall revenues coming in below expectations, driven by a small number of system orders taking longer than expected to come through.
- The company's ability to continue as a “going concern” which requires us to manage costs and obtain significant additional financing to fund our strategic plans and commercialization efforts.
- Adjournment of Special Shareholder Meeting due to lack of Quorum
- Risk that if we fail to obtain additional financing we may seek relief under applicable insolvency laws.
- The impact of adverse geopolitical and macroeconomic events
Revenue & Expenses
Visualization of income flow from segment revenue to net income